HealthDataConsortium.org Editorial Team | April 27, 2026 | Informational only — not legal or investment advice. Federal cannabis policy is in active flux; consult a licensed attorney for guidance specific to your situation.
Medical marijuana is Schedule III. Recreational marijuana is still Schedule I. The DEA hearing beginning June 29, 2026 is where that gap gets resolved — or doesn't. This analysis covers exactly what the hearing can address, what it structurally cannot, what obstacles stand between the hearing and a final rule, and what a realistic outcome timeline looks like for recreational cannabis, 280E, banking, and federal legalization.
What is the June 29, 2026 DEA Hearing About?
The DEA administrative hearing beginning June 29, 2026 is an expedited rulemaking process to evaluate the broader rescheduling of all marijuana — including recreational products — from Schedule I to Schedule III. It was announced alongside the April 23 order and replaces the prior Biden-era hearing proceedings, which were withdrawn and terminated. The new framework includes firm deadlines intended to move more efficiently toward a final rule.
The hearing allows interested parties — industry stakeholders, anti-marijuana advocacy groups, research institutions, state regulators, and others — to submit evidence and testimony on whether all marijuana meets the criteria for Schedule III classification under the Controlled Substances Act. An administrative law judge will preside. This is formal federal rulemaking, not a Congressional hearing.
Why the Prior Process Collapsed — and Why That Matters Now
The Biden-era rescheduling attempt drew approximately 43,000 public comments after a proposed rule published in May 2024 — more than any DEA rulemaking in history. Then it collapsed. In January 2025, Chief Administrative Law Judge John J. Mulrooney II raised concerns about alleged improper ex parte communications between DEA leadership and anti-rescheduling advocates including Smart Approaches to Marijuana. He granted an interlocutory appeal that halted all proceedings. In August 2025, Mulrooney retired — leaving the DEA with no administrative law judge to hear any matter at all. Multiple joint status reports through early 2026 confirmed nothing was moving.
The Trump administration responded by using the treaty compliance pathway to immediately reschedule medical marijuana through the April 23 order, bypassing the stalled process, and launching the June 29 hearing with a fresh procedural foundation. Understanding why the prior process failed matters for assessing how durable the current one is. The same opposition groups that stalled the Biden-era process — SAM in particular — have announced plans to challenge the April 23 order and participate aggressively in the June proceedings. The administration's decision to reschedule medical marijuana first is widely understood as a deliberate effort to build a more defensible legal record before the June hearing addresses recreational cannabis.
Could the June 2026 Hearing Result in Federal Marijuana Legalization?
No. The DEA hearing is a rescheduling proceeding. It can move marijuana from Schedule I to Schedule III — a meaningful but limited change. Full federal legalization would require removing marijuana from the Controlled Substances Act entirely through an act of Congress — descheduling, not rescheduling. That cannot happen through the administrative hearing process. Congressional action through legislation like the MORE Act or the Cannabis Administration and Opportunity Act would be required, and neither has passed as of April 2026.
What Would Broader Schedule III Rescheduling Actually Change?
If the June hearing results in full Schedule III rescheduling for all marijuana, the most immediate and significant change would be extending 280E tax relief to recreational cannabis businesses. Those businesses currently face effective federal tax rates of approximately 70 to 80 percent, per the Cannabis Regulators Association. Schedule III would allow standard business deductions and could reduce effective rates to approximately 20 to 30 percent — the same relief medical marijuana operators received through the April 23 order.
Beyond 280E: broader rescheduling would formally acknowledge that all marijuana has accepted medical use under federal law; reduce the legal exposure gap between state-legal recreational businesses and federal law; provide clearer pathways for researchers to study recreational-market products; and may open the banking access conversation — though it would not structurally resolve it without separate legislation.
Federal criminal penalties for recreational marijuana would not automatically change through rescheduling alone. Schedule III drugs are still controlled substances. Unauthorized possession, distribution, and manufacturing remain federal crimes at Schedule III — the penalty levels would shift downward, but the criminal framework stays intact.
What would broader Schedule III rescheduling change for recreational cannabis businesses?
The most significant change would be 280E tax relief. Recreational marijuana businesses currently face effective federal tax rates of roughly 70-80% due to Section 280E restrictions. Schedule III classification would allow standard business deductions, potentially reducing effective rates to 20-30%. Federal criminal penalties for recreational marijuana would not automatically change through rescheduling alone — those require separate Congressional action. Banking access would improve modestly for recreational operators, but structurally resolving the banking problem still requires the SAFE Banking Act or similar legislation.
The Congressional Review Act Risk
Here is the obstacle most coverage has missed entirely. Once a final rule on broader marijuana rescheduling is published in the Federal Register, Congress has a 60-day window under the Congressional Review Act (CRA) to pass a joint resolution of disapproval and block the rule. This requires simple majority votes in both chambers and a presidential signature — or a presidential veto override.
The CRA risk is real. Anti-legalization members of Congress have both the motive and the procedural mechanism. A Republican Congress could theoretically pass a CRA resolution disapproving marijuana rescheduling even while a Republican administration issued the rule — the politics of cannabis cut across party lines at the Congressional level in ways they don't at the executive level. A final rule that survives the DEA hearing process could still be blocked by Congress within 60 days of publication. This is not a theoretical edge case. It is a standard statutory risk in federal rulemaking that applies here fully.
What is the Congressional Review Act Risk for Marijuana Rescheduling?
Once a final rule on broader marijuana rescheduling publishes in the Federal Register, Congress has a 60-day window under the Congressional Review Act to pass a resolution of disapproval and block the rule. This is a real risk regardless of how the DEA hearing goes. Congress has used the CRA to block rules before, and anti-legalization members have both the motive and the procedural mechanism to attempt it here.
What No Version of Rescheduling Can Fix — Without Congress
Several policy problems in the cannabis space require Congressional action regardless of how the June hearing resolves:
Interstate commerce: Even with full Schedule III rescheduling, interstate transport and sale of marijuana would remain federally prohibited without specific legislation. Every state's cannabis market would remain legally siloed. Banking access: The Bank Secrecy Act's anti-money-laundering framework is not resolved by scheduling status. The SAFE Banking Act would be required. Expungement: Prior marijuana convictions are not affected by rescheduling. Congressional action would be required for retroactive relief. Federal employee protections: Federal workplace drug testing policies require separate regulatory or legislative action, not just a schedule change.
When Could a Final Rule on Broader Marijuana Rescheduling Come?
The June 29, 2026 hearing is the beginning of the process, not the end. Administrative hearings involve evidence submission, cross-examination, and briefing periods that typically extend months beyond the initial hearing date. Law firm Foley Hoag, tracking the proceedings closely, notes that if the process runs on the DOJ's stated timeline without major legal interference, a final rule could arrive as early as late 2026. Legal challenges, court injunctions, or Congressional action under the CRA could push that well into 2027 or beyond. The DOJ announced “firm deadlines” — but firm deadlines in federal rulemaking are frequently aspirational rather than legally binding.
What could a final rule on broader marijuana rescheduling come?
If the process runs on the DOJ's stated timeline without major legal interference, a final rule on broader marijuana rescheduling could arrive as early as late 2026. Legal challenges, court injunctions, or Congressional action under the Congressional Review Act could push that into 2027 or later. The June 29 hearing is the beginning of the process — administrative hearings involve evidence submission, cross-examination, and briefing periods that typically extend months beyond the initial hearing date.
What to Watch Between Now and June 29
These are the five developments most likely to determine whether the June hearing moves efficiently toward a final rule or hits another wall:
Court filings from SAM or allied groups seeking a preliminary injunction against the April 23 order or the June hearing. An injunction before June 29 would delay or halt proceedings before they begin. The DEA's Federal Register notice governing the June hearing — this will set specific evidence deadlines, participation requirements, and procedural rules. Businesses and advocacy groups with a stake in the outcome should engage counsel to evaluate participation. IRS and Treasury guidance on 280E retroactive relief — relevant to medical operators and tax counsel across the industry. SAFER Banking Act developments — any legislative movement on cannabis banking would significantly change the stakes of the rescheduling debate. Congressional signaling on CRA action — watch floor statements and committee activity for early signals about whether members intend to attempt a CRA resolution disapproving the eventual final rule.
For the complete account of what the April 23 order established — including the June 22 DEA registration deadline for medical operators — see the primary Schedule III analysis. For what the rescheduling did not change, see the rescheduling versus legalization breakdown. For the patient and operator impact guide, see the June 22 deadline and patient guide. For the broader context of the multi-track federal cannabis legal landscape, see the federal cannabis law explainer. For current state-by-state legality, see the delta-9 state legal guide.
When None of These Answers Are Enough
If you're a cannabis business operator, investor, patient, or someone with a personal legal situation affected by federal marijuana law, this analysis provides an accurate policy map — but not legal advice. A licensed attorney with cannabis law experience in your jurisdiction is the right resource for situation-specific guidance. HealthDataConsortium.org will update this stack as the June 29 hearing proceeds, as legal challenges develop, and as IRS, Treasury, and DEA guidance issues on the practical implications of the April 23 order.
This content is for informational purposes only and does not constitute legal or investment advice. Federal cannabis policy is in active flux; consult a licensed attorney for guidance specific to your situation. HealthDataConsortium.org is an independent analytical publication and is not affiliated with any government entity or cannabis industry organization.
